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Available online 21 October 2015AbstractBackground: Injury to the medial collateral ligament (MCL) of the knee joint is the most common ligament injury of the knee. Ligament healing
generally takes a long time. Micro-ribonucleic acid (miRNA) is one of the noncoding RNAs and plays a crucial role in physiological function;
miRNA (miR)-210 is known as a potent factor of angiogenesis, which is an important initiator of ligament healing. The purpose of this study is
to examine the effect of local injection of double-stranded (ds) miR-210 on the healing of the MCL of rat knee joint.
Methods: MCLs of Sprague-Dawley rats were cut transversely. After the fascia and skin were sutured, dsmiR-210 or control dsRNAwas injected
into the injured site of MCL. At 2 weeks and 4 weeks, histological analysis and immunofluorescence staining of vascular endothelial growth
factor, isolectin B4, collagen type 1, and Ki67 as well as a mechanical test were performed. Analysis of complementary deoxyribonucleic acid
(cDNA) microarray data was performed at 1 week.
Results: Histological analysis showed that parallel fibres in the injured site were organised at 2 weeks and became thicker at 4 weeks in the miR-
210-treated group, whereas the injured site in controls was filled with loose fibrous tissues and was thinner than that in the miR-210-treated
group. The number of blood vessels in the miR-210-treated group was significantly higher than that in controls ( p < 0.05), and vascular
endothelial growth factor, Ki67, and collagen type 1 in the miR-210-treated group were intensely expressed in the repaired site as compared to
the control group. The mechanical test indicated that the ultimate failure load in the miR-210-treated group was significantly higher than that in
the control group at 2 weeks. The cDNA microarray analysis showed significant upregulation of genes related to cell proliferation and cell
differentiation, and genes involved in negative regulation of apoptosis.
Conclusion: This study showed that local injection of dsmiR-210 could accelerate MCL healing in rat, which is likely due to stimulation of
angiogenesis at the healing site.
Copyright © 2015 Asia Pacific Knee, Arthroscopy and Sports Medicine Society. Published by Elsevier (Singapore) Pte Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Injury to the medial collateral ligament (MCL) of the knee is
the most common knee ligament injury that occurs mainly in* Corresponding author. Faculty of Medicine, University of Hasanuddin,
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article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nyoung individuals during sports activity.1,2 MCL injury, even
acute Grade 3 injury, can heal by nonoperative treatment.3,4 It
generally takes 5e7 weeks for athletes to heal and return to full
competition under awell-controlled rehabilitation programme.5
However, some cases do not heal and lead to continuous
instability, subsequently causing dysfunction of the knee joint.
Novel strategies for more effective and early healing of MCL
injury by nonoperative treatment should be developed.e Society. Published by Elsevier (Singapore) Pte Ltd. This is an open access
c-nd/4.0/).
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(miRNA) in the pathogenesis of human diseases such as
cancers, heart diseases, and neuron disorders has been recog-
nised. These miRNAs are a set of approximately 22-
nucleotide, small noncoding RNAs that negatively regulate
gene expressions through binding to the 30 untranslated region
of mRNA of their target genes.6,7 The miRNAs play a crucial
role in various cellular processes such as cell proliferation,
differentiation, and apoptosis, which result in tissue speciali-
sation and homeostasis. Therefore, an abnormal expression of
miRNAs has been linked to several diseases.8e11 Therapeutic
trials to regulate endogenous expression of miRNA in vivo by
administration of synthetic miRNA or antisense miRNA with
some modifications have been reported.12e14 Lanford et al15
demonstrated the successful treatment of chimpanzees with
hepatitis C virus infection by the administration of a locked
nucleic acid-modified oligonucleotide complementary to miR-
122. Thus, the therapeutic strategy targeting miRNAs is a
novel and promising avenue to treat human diseases.
Angiogenesis has been recognised as an important initiator
of healing and remodelling of tissues including liga-
ments.16e18 Several reports demonstrated induction of angio-
genesis/vasculogenesis by administration of drugs, cytokines,
and cells to the injured ligaments.19e22 A well-known potent
factor of angiogenesis is miRNA (miR)-210. It is upregulated
in endothelial cells in response to hypoxia, which affects cell
survival, migration, and differentiation; even in normoxic
condition, overexpression of miR-210 could induce the for-
mation of capillary-like structures with vascular endothelial
growth factor (VEGF)-driven cell migration.23e25 It has been
reported that local administration of miR-210 can promote
tissue healing in vivo.26,27 Therefore, we hypothesised that
local injection of synthetic miR-210 into the injured MCL
could accelerate ligament healing. The purpose of this study is
to examine the effect of local injection of synthetic miR-210
on the acceleration of ligament healing in a rat MCL injury
model.
Materials and methods
All procedures were performed according to the guidelines
for animal experimentation of Hiroshima University, and with
the approval of the Committee of Research Facilities for
Laboratory Animal Sciences, Graduate School of Biomedical
Sciences, Hiroshima University.Preparation of double-stranded RNADouble-stranded (ds) miR-210 (sequences 66-CUG-UGC-
GUG-UGA-CAG-CGG-CUG-A-87 and 87-AGC-CCC-UGC-
CCA-CCG-CAC-ACU-G-66; B-Bridge International, Moun-
tain View, CA, USA) and ds control RNA [sequences 51-ATC-
CGC-GCG-ATA-GTA-CGT-A-31 and 31-overhang dTdT/
dTdT (sense/antisense) siRNA negative control; B-Bridge In-
ternational] were prepared for the local injection according to
a previous report.27 The dsRNAwas mixed with atelocollagen,
which is a highly purified collagen type 1 isolated from calfdermis by pepsin treatment (Koken, Tokyo, Japan). Equal
volumes of atelocollagen (10 mL) as a carrier of dsRNA and
dsRNA solution (20 mg/10 mL) were combined and mixed by
rotation at 4C for 20 minutes, and a total of 20 mL dsRNA-
eatelocollagen complex was injected into the injured site of
MCL.Animal modelTwelve-week-old male Sprague-Dawley rats were used in
this study. A total of 41 rats were anaesthetised with an
intraperitoneal injection of 1 mL/kg pentobarbital sodium.
Medial skin incision was applied at the right knee joint of the
rats, and the MCL was cut transversely using a scalpel. The
fascia and skin were sutured, and briefly, the dsRNA-
eatelocollagen complex was injected into the injured site of
MCL. Twenty-one rats (control animals) were given ds control
RNA injection, and another 21 rats were assigned to the miR-
210-treated group. Five rats, on which sham surgery was
performed, were used for mechanical testing.Histological analysisAt 2 weeks and 4 weeks after injection, 10 rats in each
group (2 weeks, 5 rats; 4 weeks, 5 rats) were sacrificed by an
overdose of anaesthesia. The MCL was harvested and
embedded in optical cutting temperature compound (Sakura
Finetek USA, Inc., Torrance, CA, USA). Frozen serial sections
of 6 mm thickness were prepared and Masson trichrome
staining was performed. All specimens were given a histo-
logical score from 0 to 6 according to the following parame-
ters: degree of retraction, tissue coverage, predominant cell
type, and collagen fibre organisation as described previously.28
All specimens were evaluated by two authors (T.N. and
M.A.U.) without any knowledge of treatment, in a blinded
fashion.Mechanical testingThe ultimate failure loads of the MCL in both groups
(n ¼ 5) at 2 weeks and 4 weeks, and the sham group (n ¼ 5)
were measured using a conventional tensile tester (1840NT/
500; AIKOH Engineering, Osaka, Japan). All specimens were
dissected free of all skin, subcutaneous muscle, ligament, and
menisci, leaving the MCL. The dissected specimens were set
into a cylinder of polymethylmethacrylate cement so that the
load was directed along the longitudinal axis of the MCL. The
ultimate failure load was measured at a cross-head speed of
200 mm/minute until the femureMCLetibia complex failed.
Normal ligaments of the rats that received sham operation
used as the basic standard.ImmunohistochemistryFor immunofluorescence staining of VEGF, isolectin B4,
collagen type 1, and Ki67, frozen sections at 2 weeks were
fixed with 4.0% paraformaldehyde at 4C for 5 minutes, and
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bridge, MA, USA), fluorescein-labelled GSL I-isolectin B4
(Vector Laboratories, Burlingame, CA, USA), rabbit anti-
Ki67 (Neomarkers, Fremont, CA, USA), and goat poly-
clonal anticollagen type 1 antibody (Santa Cruz Bio-
technologies, Santa Cruz, CA, USA). The secondary
antibodies were Alexa Fluor 568-conjugated goat antirabbit
immunoglobulin G for VEGF and Ki67, and Alexa Flour 488-
conjugated rabbit antigoat immunoglobulin G for collagen
type 1 (all from Molecular Probes/Invitrogen, Carlsbad, CA,
USA). DAPI (40,6-Diamidino-2-phenylindole dihydro-
chloride) solution was applied for 5 minutes to detect nuclear
staining.
For the evaluation of newly formed vessels in the MCL,
five microscopic areas (250 mm  250 mm) from each spec-
imen at 200 magnification were randomly chosen (n ¼ 5 in
each group). Capillaries were recognised as isolectin B4-
positive tubular structures and counted by the two authors
(T.N. and M.A.U.).Microarray analysisTotal RNA for DNA microarray was extracted from the
repaired site in each group using TRIzol (Life Technologies,
Carlsbad, California, USA), according to the manufacturer's
instructions. One microgram of the total RNA was used forFigure 1. (A) Gross appearance of medial collateral ligament (MCL). Arrow indic
groups. Bar indicates 200 mm. (C) Histological score of both groups. *p < 0.05. mthe DNA microarray analysis. After amplification, the RNA
sample in each group (n ¼ 1 in each group) was labelled with
Cy3 or Cy5, and hybridised with 3D-Gene Rat Oligo chip
24k (Toray Industries Inc., Tokyo, Japan). After hybrid-
isation, hybridisation signals were scanned using 3D Gene
Scanner 3000 (Toray Industries Inc.), and all the data from
scanned images were scaled by global normalisation. From
microarray data, the differentially expressed genes during
MCL healing were analysed by gene ontology and pathway
enrichment analysis. Gene ontology analysis was performed
using GeneCodis2.0 software to integrate differentially
expressed genes and to evaluate groups of genes with similar
biological function.29e31 GenMAPP (gene map annotator and
pathway profiler), which allows us to view and analyse
microarray data on biological pathways, was also used32 to
identify which pathways are affected by miR-210 during
MCL healing.Statistical analysisThe ManneWhitney U test was used for the detection of
differences in the histological scores and vessel numbers be-
tween the two groups, and multiple comparisons in the me-
chanical testing were performed using the TukeyeKramer's
post hoc test. A p value of < 0.05 was considered statistically
significant.ates the injured site of MCL. (B) Masson trichrome staining of MCL in both
iR-210 ¼ microRNA-210.
Figure 2. Ultimate failure load of medial collateral ligament (MCL).
*p < 0.05. miR-210 ¼ microRNA-210.
Figure 3. (A) Immunohistochemistry of isolectin B4 in both groups. Bar indicate
vascular endothelial growth factor (VEGF) in both groups. Bar indicates 100 mm.
factor; DAPI (40,6-Diamidino-2-phenylindole dihydrochloride) is a fluorescent stai
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treated group were macroscopically observed to be continuous
and bulkier as compared to the control group. In the control
group, the resected area of MCL was filled with scar tissues.
At 4 weeks, the repaired site of MCL in the control group was
thinner than that in the miR-210-treated group (Figure 1A).Histological analysisHistological analysis using Masson trichrome staining
revealed that parallel fibres in the injured site were organised
at 2 weeks and became thicker at 4 weeks in the miR-210-
treated group, as compared to the control group. On the
other hand, the injured sites in the control group were filled
with loose fibrous tissues and were thinner than those in miR-s 100 mm. (B) Vessel number in both groups. (C) Immunohistochemistry of
*p < 0.05. miR-210 ¼ microRNA-210; VEGF ¼ vascular endothelial growth
n that binds strongly to A-Trich regions in DNA.
Table 1
The result of gene ontology analysis.
Up regulation (>2 fold change) Gene count
GO:0045944: positive regulation of transcription from
RNA polymerase II promoter
281
GO:0042493: response to drug 181
GO:0043066: negative regulation of apoptosis 155
GO:0008284: positive regulation of cell proliferation 139
GO:0045893: positive regulation of transcription,
DNA-dependent
137
GO:0014070: response to organic cyclic compound 126
GO:0006355: regulation of transcription, DNA-dependent 111
GO:0000122: negative regulation of transcription from
RNA polymerase II promoter
105
GO:0006351: transcription, DNA-dependent 100
GO:0030154: cell differentiation 91
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samples from the miR-210-treated group was significantly
higher than that from the control group at 2 weeks (1.6 ± 2.2
vs. 5.6 ± 0.54) and 4 weeks (4.5 ± 0.5 vs. 5.8 ± 0.4;
Figure 1C). A mechanical test showed that the ultimate failure
load in the miR-210-treated group (19.8 ± 2.7 N) was
significantly higher than that in the control group (7.5 ± 3.4 N)
at 2 weeks, but it was significantly lower than that in the sham
group (32.9 ± 1.2 N; p < 0.05). At 4 weeks, there was no
significant difference of the ultimate failure load between the
miR-210-treated group (39.8 ± 5.5 N) and the control group
(33.7 ± 8.3 N), although the ultimate failure load in the miR-
210-treated group was likely to be higher than that in the
control group ( p ¼ 0.14; Figure 2).GO:0045892: negative regulation of transcription,
DNA-dependent
90
GO:0051384: response to glucocorticoid stimulus 78Immunofluorescent stainingGO:0007275: multicellular organismal development 74
GO:0007507: heart development 65
GO:0006357: regulation of transcription from RNA
polymerase II promoter
54
Down regulation (<0.5 fold change) Gene count
GO:0008285: negative regulation of cell proliferation 129
GO:0006355: regulation of transcription, DNA-dependent 128
GO:0043065: positive regulation of apoptosis 113
GO:0007275: multicellular organismal development 100
GO:0030308: negative regulation of cell growth 100
GO:0045893: positive regulation of transcription,
DNA-dependent
100
GO:0007519: skeletal muscle tissue development 92
GO:0006811: ion transport 81
GO:0043066: negative regulation of apoptosis 81To examine the angiogenesis during MCL healing, isolectin
B4 staining was performed to detect the blood vessels. At 2
weeks, abundant blood vessels in the repaired tissues were
observed in the miR-210-treated group as compared to the
control group (Figure 3A). The number of blood vessels in the
repaired tissues of the miR-210-treated group (158.1 ± 11.5/
mm2) was significantly higher than that in the control group
(72 ± 6.1/mm2; p < 0.05; Figure 3B). Immunohistochemistry
staining of VEGF (an essential protein for angiogenesis and
vasculogenesis) in the repaired tissues revealed that VEGF in the
miR-210-treated group was intensely expressed in the repaired
sites as compared to that in the control group (Figure 3C).GO:0030154: cell differentiation 64
GO:0042493: response to drug 61DNA microarray analysis
GO:0006096: glycolysis 56
GO:0005975: carbohydrate metabolic process 54
GO:0006810: transport 51The cDNA microarray analysis of tissues from the repaired
sites of both groups was performed at 1 week after the pro-
cedure using 3D-Gene Rat Oligo chip 24k (Toray Industries
Inc.). Gene ontology analysis revealed that the expression of
genes related to cell proliferation, differentiation, and negative
regulation of apoptosis was remarkably upregulated and gene
expression related to negative regulation of cell proliferation,
negative regulation of cell growth, and positive regulation of
apoptosis was downregulated (Table 1). These results indi-
cated that miR-210 could stimulate cell differentiation and
proliferation as well as negatively regulate cell apoptosis in the
repaired site of MCL. To confirm the effect of miR-210 in cell
proliferation as well as to identify target cells of miR210
treatment in the repaired site, immunohistochemistry was
performed. A lot of Ki67 (a marker of cell proliferation)-
positive cells were observed in the repaired site of MCL in
the miR-210-treated group as compared to that of the control
group, and these cells were merged with isolectin B4- and
collagen type 1-positive cells (Figure 4). Thus, miR-210 might
increase endothelial cells and collagen type 1-producing cells
during MCL healing. Pathway enrichment analysis showed
that retinol metabolism, prostaglandin synthesis and regula-
tion, adipogenesis, triacylglyceride synthesis, type 2 interferon
signalling, and cholesterol metabolism were upregulated (>2-
fold change; Table 2).Discussion
Previous reports showed that several therapeutic trials using
cells, cytokines, and platelet-rich plasma for accelerating
MCL healing were conducted.21,22,33 Among the cytokines for
ligament healing, VEGF plays a crucial role in angiogenesis, a
crucial event in the healing process of injured MCL.22 In the
natural healing process of ligaments, the VEGF expression
crested between 5 days and 9 days postinjury.17,34 Additional
expression of VEGF such as local administration does not
affect the mechanical properties, which indicated that proper
levels of VEGF and other factors may be required for func-
tional ligament healing.35,36 Another report demonstrated that
local administration of peripheral blood-derived CD34þ cells
could promote MCL healing via vasculogenesis.21 In this
study, we have shown that local injection of dsmiR-210 could
accelerate MCL healing. The ultimate failure load in the miR-
210-treated group was significantly higher than that of the
control group at 2 weeks. At 4 weeks, ultimate failure load in
the miR-210-treated group was likely to be high compared to
that in the control group, but there was no statistically sig-
nificant difference. The ultimate failure load in both groups
Figure 4. Immunohistochemistry of isolectin B4, Ki67, and collagen type 1 in both groups. Bar indicates 100 mm. miR-210 ¼ microRNA-210.
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effect of the administration of dsmiR-210 on the mechanical
properties might not be detected in the rat model. At 2 weeks,
collagen type 1 expression and angiogenesis were upregulated
in the miR-210-treated group. Most athletes with ligament
injury generally can return to full competition 5e7 weeks after
injury.5 Early intervention for the injured MCL would be
important for upregulation of angiogenesis and synthesis of
collagen type 1, subsequently yielding better mechanical
properties. In this study, a single-dose injection was adminis-
tered. However, even with a single-dose injection, the
expression of many genes in the injected site was altered at 1
week. Previous reports showed that a single-dose injection of
miRNA could enhance the therapeutic effects; therefore, only
a single-dose injection to the injured MCL will be
feasible.13,27,37,38 However, our study showed only one timepoint of injection. The effect of repeated injections of miR-210
on MCL healing, including the adverse effects, is unclear. As a
single injection of miR-210 could enhance collagen type 1
expression, there is a possibility that repeated injections of
miR-210 can show better results than a single injection. The
results of this study suggested that local injection of miR-210
can be a potential novel treatment strategy to accelerate the
healing of an injured ligament, thus enabling injured athletes
to return to full competition earlier.
An advantage of miRNA therapy is that it does not require
tissue harvesting, including isolation and purification of cells
or platelet-rich plasma. Thus, miRNA therapy is simple in its
construction and potentially used as a novel drug. Further-
more, multifactorial effects of miRNA for obtaining functional
ligament properties will be expected as its targeting many
genes based on computational analysis. In addition to its effect
Table 2
The results of pathway enrichment analysis.
MAPP name Gene
number
Z Score PermuteP
>2 fold
change
1 Retinol metabolism 8 5.424 0
2 Prostaglandin synthesis and
regulation
7 4.93 0
3 Adipogenesis 10 2 0.06
4 Triacylglyceride synthesis 3 2.13 0.065
5 Type II interferon signaling 4 2.079 0.066
6 Cholesterol metabolism 3 2.035 0.094
<0.5 fold
change
1 Electron transport chain 44 12.524 0
2 Striated muscle contraction 22 11.405 0
3 TCA cycle 16 9.26 0
4 Oxidative phosphorylation 25 9.224 0
5 Glycolysis and
gluconeogenesis
16 7.285 0
6 Glycogen metabolism 8 2.967 0.007
7 Beta oxidation meta pathway 8 2.967 0.007
8 Fatty acid beta oxidation 8 2.766 0.014
9 Diurnally regulated genes
with circadian orthologs
9 2.614 0.019
10 Mitochondrial LC-fatty acid
beta-oxidation
5 2.775 0.02
11 Beta oxidation of unsaturated
fatty acids
3 3.358 0.022
12 Fatty acid beta oxidation 1 6 2.231 0.041
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in other biological processes, including mitochondrial meta-
bolism, DNA repair, regulation of apoptosis, and cell prolif-
eration.25 Gene ontology enrichment analysis of our study
indicated significant upregulation of genes that are positively
involved in transcription, cell proliferation, and cell differen-
tiation, as well as genes that negatively regulate apoptosis in
the samples derived from miR-210-treated genes, as compared
to those from the control group. These results suggested that
gene expression related to tissue repair was upregulated by
miR-210 treatment in the injured sites of MCL, an effect that
seem to specifically stimulate angiogenesis and collagen type
1 production. Pathway enrichment analysis showed that retinol
metabolism was activated by miR-210 administration during
MCL healing. The retinol metabolism pathway plays an
important role in normal development and disease.39 Retinoic
acid, which is the main derivative of retinol (vitamin A), is
essential for regulating several biological processes including
differentiation, proliferation, and apoptosis. Moreover, reti-
noids regulate stem cell differentiation via transcription acti-
vation.40 The potential of retinoic acid in regenerative
medicine has been examined.41 Thus, the results of this study
are consistent with those reported in the literature. Further
studies are needed to explore the role of retinoic acid in the
healing process of MCL and its relationship with miR-210. In
this study, microarray analysis was performed at 1 week
postinjection because there was a significant difference in the
histological findings at 2 weeks. The early change of the gene
expression is important to analyse the mechanism of healing.
Significant events such as angiogenesis in the tendon healingoccur at around 1 week; therefore, we performed microarray
analysis at 1 week.
For clinical application, the biological safety of miRNA
treatment should be validated. Expressions of miRNA have a
role in several human diseases such as cancer. In this study, no
adverse effects were observed, but we could not confirm the
distribution of administered miR-210 in the rats. It has been
reported that miR-210 negatively regulates cancer cell pro-
liferation.42 However, further studies are needed to examine its
safety, including investigation of its adverse effects, prior to its
application in clinical settings. Clinical trials of miRNA
replacement therapy or antisense oligonucleotides of miRNA
are currently ongoing; hence, miRNA targeting therapy is
gradually being recognised.43,44
In conclusion, our study showed that local injection of miR-
210 could accelerate MCL healing. Further studies are
required to gain more detailed insights into its mechanism of
action. Local injection of miR-210 into the injured MCL is
one of the potential therapeutic options in the future since
accumulating evidence suggested that the effectiveness and
safety of miRNA therapy are promising.
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